Cargando…

Technical Note: Break‐even dose level for hypofractionated treatment schedules

PURPOSE: To derive the isodose line R relative to the prescription dose below which irradiated normal tissue (NT) regions benefit from a hypofractionated schedule with an isoeffective dose to the tumor. To apply the formalism to clinical case examples. METHODS: From the standard biologically effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Böhlen, Till Tobias, Germond, Jean‐François, Bourhis, Jean, Vozenin, Marie‐Catherine, Bailat, Claude, Bochud, François, Moeckli, Raphaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298418/
https://www.ncbi.nlm.nih.gov/pubmed/34609744
http://dx.doi.org/10.1002/mp.15267
_version_ 1784750704495165440
author Böhlen, Till Tobias
Germond, Jean‐François
Bourhis, Jean
Vozenin, Marie‐Catherine
Bailat, Claude
Bochud, François
Moeckli, Raphaël
author_facet Böhlen, Till Tobias
Germond, Jean‐François
Bourhis, Jean
Vozenin, Marie‐Catherine
Bailat, Claude
Bochud, François
Moeckli, Raphaël
author_sort Böhlen, Till Tobias
collection PubMed
description PURPOSE: To derive the isodose line R relative to the prescription dose below which irradiated normal tissue (NT) regions benefit from a hypofractionated schedule with an isoeffective dose to the tumor. To apply the formalism to clinical case examples. METHODS: From the standard biologically effective dose (BED) equation based on the linear‐quadratic (LQ) model, the BED of an NT that receives a relative proportion r of the prescribed dose per fraction for a given α/β‐ratio of the tumor, (α/β)(T), and NT, (α/β)(NT), is derived for different treatment schedules while keeping the BED to the tumor constant. Based on this, the “break‐even” isodose line R is then derived. The BED of NT regions that receive doses below R decreases for more hypofractionated treatment schedules, and hence a lower risk for NT injury is predicted in these regions. To assess the impact of a linear behavior of BED for high doses per fraction (>6 Gy), we evaluated BED also using the LQ‐linear (LQ‐L) model. RESULTS: The formalism provides the equations to derive the BED of an NT as function of dose per fraction for an isoeffective dose to the tumor and the corresponding break‐even isodose line R. For generic α/β‐ratios of (α/β)(T )= 10 Gy and (α/β)(NT )= 3 Gy and homogeneous dose in the target, R is 30%. R is doubling for stereotactic treatments for which tumor control correlates with the maximum dose of 100% instead of the encompassing isodose line of 50%. When using the LQ‐L model, the notion of a break‐even dose level R remains valid up to about 20 Gy per fraction for generic α/β‐ratios and [Formula: see text]. CONCLUSIONS: The formalism may be used to estimate below which relative isodose line R there will be a differential sparing of NT when increasing hypofractionation. More generally, it allows to assess changes of the therapeutic index for sets of isoeffective treatment schedules at different relative dose levels compared to a reference schedule in a compact manner.
format Online
Article
Text
id pubmed-9298418
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92984182022-07-21 Technical Note: Break‐even dose level for hypofractionated treatment schedules Böhlen, Till Tobias Germond, Jean‐François Bourhis, Jean Vozenin, Marie‐Catherine Bailat, Claude Bochud, François Moeckli, Raphaël Med Phys BIOLOGICAL PHYSICS AND RESPONSE PREDICTION PURPOSE: To derive the isodose line R relative to the prescription dose below which irradiated normal tissue (NT) regions benefit from a hypofractionated schedule with an isoeffective dose to the tumor. To apply the formalism to clinical case examples. METHODS: From the standard biologically effective dose (BED) equation based on the linear‐quadratic (LQ) model, the BED of an NT that receives a relative proportion r of the prescribed dose per fraction for a given α/β‐ratio of the tumor, (α/β)(T), and NT, (α/β)(NT), is derived for different treatment schedules while keeping the BED to the tumor constant. Based on this, the “break‐even” isodose line R is then derived. The BED of NT regions that receive doses below R decreases for more hypofractionated treatment schedules, and hence a lower risk for NT injury is predicted in these regions. To assess the impact of a linear behavior of BED for high doses per fraction (>6 Gy), we evaluated BED also using the LQ‐linear (LQ‐L) model. RESULTS: The formalism provides the equations to derive the BED of an NT as function of dose per fraction for an isoeffective dose to the tumor and the corresponding break‐even isodose line R. For generic α/β‐ratios of (α/β)(T )= 10 Gy and (α/β)(NT )= 3 Gy and homogeneous dose in the target, R is 30%. R is doubling for stereotactic treatments for which tumor control correlates with the maximum dose of 100% instead of the encompassing isodose line of 50%. When using the LQ‐L model, the notion of a break‐even dose level R remains valid up to about 20 Gy per fraction for generic α/β‐ratios and [Formula: see text]. CONCLUSIONS: The formalism may be used to estimate below which relative isodose line R there will be a differential sparing of NT when increasing hypofractionation. More generally, it allows to assess changes of the therapeutic index for sets of isoeffective treatment schedules at different relative dose levels compared to a reference schedule in a compact manner. John Wiley and Sons Inc. 2021-10-22 2021-11 /pmc/articles/PMC9298418/ /pubmed/34609744 http://dx.doi.org/10.1002/mp.15267 Text en © 2021 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle BIOLOGICAL PHYSICS AND RESPONSE PREDICTION
Böhlen, Till Tobias
Germond, Jean‐François
Bourhis, Jean
Vozenin, Marie‐Catherine
Bailat, Claude
Bochud, François
Moeckli, Raphaël
Technical Note: Break‐even dose level for hypofractionated treatment schedules
title Technical Note: Break‐even dose level for hypofractionated treatment schedules
title_full Technical Note: Break‐even dose level for hypofractionated treatment schedules
title_fullStr Technical Note: Break‐even dose level for hypofractionated treatment schedules
title_full_unstemmed Technical Note: Break‐even dose level for hypofractionated treatment schedules
title_short Technical Note: Break‐even dose level for hypofractionated treatment schedules
title_sort technical note: break‐even dose level for hypofractionated treatment schedules
topic BIOLOGICAL PHYSICS AND RESPONSE PREDICTION
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298418/
https://www.ncbi.nlm.nih.gov/pubmed/34609744
http://dx.doi.org/10.1002/mp.15267
work_keys_str_mv AT bohlentilltobias technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules
AT germondjeanfrancois technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules
AT bourhisjean technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules
AT vozeninmariecatherine technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules
AT bailatclaude technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules
AT bochudfrancois technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules
AT moeckliraphael technicalnotebreakevendoselevelforhypofractionatedtreatmentschedules